US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism
Pulmonary Embolism
About this trial
This is an interventional prevention trial for Pulmonary Embolism focused on measuring Vena Cava Filters, Embolic Protection Devices
Eligibility Criteria
Inclusion Criteria:
- Aged 18 years or older
- Willing to comply with the specified follow-up requirements including contrast enhanced CTs for the 9-month duration of the study
- For female subjects of childbearing potential: a negative pregnancy test within 48 hours prior to the implantation procedure
- For the prophylactic cohort, high risk VTE denoted by either:
Caprini score > 8 for surgical ICU, Parvizi score ≥ 150 for TKA (total knee replacement), ISS score ≥ 24 for trauma.
- For the therapeutic cohort, documented VTE per the following:
Pulmonary thromboembolism when anticoagulants are contraindicated, Failure of anticoagulant therapy in thromboembolic diseases, Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced.
- Requirement of temporary PE protection (8 weeks) based on clinical judgment
- Fully informed subject or caretaker consent having executed an Institutional Review Board (IRB) or approved informed consent.
Exclusion Criteria:
- Expected high VTE risk to extend beyond 8 weeks
- Vena cava filter currently implanted
- History of abdominal or pelvic radiation therapy
- Previous IVC filter placement/retrieval within 6 months prior to randomization
- Confirmed positive blood cultures within the last 48 hours if there is bacteremia
- Known sensitivity to radiographic contrast medium that cannot be adequately prophylactically pre-medicated
- Known allergy or intolerance to IVC filter materials (i.e. PDSII absorbable suture)
- Pregnant, lactating, or plans to become pregnant during investigation follow-up period
- Renal insufficiency (GFR < 60) or requiring renal replacement therapy
- IVC effective diameter (D) <16 mm or >28 mm anywhere within L1-L4, D = √(AP*Lat)
- Less than 7cm from inferior-most renal vein to the iliac vein confluence
- Duplication of the IVC
- Any thrombus or occlusion in IVC on pre-procedural CT cavogram
- Life expectancy of < 12 months
Sites / Locations
- University of Colorado Anschutz Medical Campus
- IU Health University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Therapeutic
Prophylactic - Test
Prophylactic - Control
The therapeutic arm will include subjects with diagnosed symptomatic VTE (PE and/or DVT). Each subject will receive an Adient absorbable filter to help prevent a subsequent PE. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
The Prophylactic - Test arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive an Adient absorbable filter to help prevent PE in addition to being administered current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
The Prophylactic - Control arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit.